Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:03 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 557 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene sequencing Clear all
Terminated Phase 1Phase 2 Interventional Results available

Survival Prolongation by Rationale Innovative Genomics

NCT03386929
View directory record Official record
Conditions
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Interventions
Avelumab, Axitinib, Palbociclib
Drug
Lead sponsor
Worldwide Innovative Network Association
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Nov 3, 2026, 1:03 PM EST
Enrolling by invitation Not applicable Interventional

Assessing Microbiome in Primary Anterior Cervical Fusion Patients

NCT07877766
View directory record Official record
Conditions
Cervical Stenosis, Myelopathy, Cervical Spondylosis With Myelopathy, Degenerative Disc Disease, Radiculopathy
Interventions
Primary Anterior Cervical Discectomy Procedures
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting No phase listed Observational

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Terminated Phase 2 Interventional

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
Interventions
Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Placebo, Folic acid 400 -1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg
Drug · Biological · Dietary Supplement
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Yuma, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting No phase listed Observational

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

NCT06207032
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Birmingham, Alabama • Whittier, California • Norwich, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Completed No phase listed Observational

Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation

NCT02132858
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Nov 3, 2026, 1:03 PM EST
Completed Phase 2 Interventional Results available

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

NCT01726738
View directory record Official record
Conditions
Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
Interventions
BRAF inhibitor dabrafenib and MEK inhibitor trametinib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting Not applicable Interventional

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

NCT05621291
View directory record Official record
Conditions
B-All, Acute Lymphoblastic Leukemia
Interventions
NGS testing
Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Nov 3, 2026, 1:03 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Genotype-Phenotype Urothelial Cancer Registry

NCT00902590
View directory record Official record
Conditions
Urothelial Cancer, Renal Pelvis Cancer, Ureter Cancer, Bladder Cancer
Interventions
saliva sample and questionaire, saliva sample, questionaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,519 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2027
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Development of an Optimal Approach to Return of Results for Next-generation Sequencing for Prenatal Diagnosis

NCT02255825
View directory record Official record
Conditions
Major Fetal Anomaly
Interventions
Whole Genome Sequencing, Amniocentesis, Psychosocial assessment
Genetic · Procedure · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Nov 3, 2026, 1:03 PM EST
Completed Phase 2 Interventional Results available

Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

NCT01431391
View directory record Official record
Conditions
Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
Interventions
sipuleucel-T, leuprolide acetate
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
14
States / cities
Homewood, Alabama • La Jolla, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 3, 2026, 1:03 PM EST
Completed Not applicable Interventional Results available

An Adaptive Intervention for Adolescents at Risk for Suicide: A Pilot SMART

NCT03838198
View directory record Official record
Conditions
Suicide, Self Harm
Interventions
MI-Enhanced Safety Plan at Hospitalization (1st Component), MI-Enhanced Text Boosters (2nd Component), MI-Enhanced Booster Call (3rd Component)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 17 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting No phase listed Observational

Genetics of Neonatal Encephalopathy and Related Disorders

NCT07165938
View directory record Official record
Conditions
Neonatal Encephalopathy, Hypoxic Ischaemic Encephalopathy (HIE)
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemoradiation for Resectable Glioblastoma

NCT04209790
View directory record Official record
Conditions
Glioblastoma, Surgery, High Grade Glioma
Interventions
Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
Radiation · Drug · Procedure
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 1:03 PM EST
Completed No phase listed Observational

Adult Patients With Undiagnosed Conditions and Their Responses to Clinically Uncertain Results From Exome Sequencing

NCT03605004
View directory record Official record
Conditions
Undiagnosed Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Nov 3, 2026, 1:03 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive-Motor Training for AD/ADRD Prevention

NCT07160582
View directory record Official record
Conditions
MCI, Aging
Interventions
Novel CogXergaming Training, Exercise and Education Training Program
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
55 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebellar Involvement in Cognitive Sequencing

NCT06108336
View directory record Official record
Conditions
Effects of Cerebellar Stimulation on Brain Activation
Interventions
TMS during sequence-demanding task, No TMS during sequence-demanding task, TMS during non-sequence-demanding task, No TMS during non-sequence-demanding task
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Completed Not applicable Interventional

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

NCT02132845
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
cytology specimen collection procedure, targeted therapy, therapeutic procedure, laboratory biomarker analysis
Other · Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Nov 3, 2026, 1:03 PM EST
Recruiting No phase listed Observational

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

NCT02090530
View directory record Official record
Conditions
Cancer
Interventions
Biospecimen collection
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Nov 3, 2026, 1:03 PM EST
Not listed Phase 1 Interventional

Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2

NCT02009709
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin 0.1% ophthalmic solution, CCL-VARIO UV lamp, CCL-VARIO at 18 mW/cm2
Drug · Device
Lead sponsor
Robert Mack, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Nov 3, 2026, 1:03 PM EST
Completed Not applicable Interventional

Next Generation Sequencing Screening for Embryonic Ploidy Status

NCT02032264
View directory record Official record
Conditions
Infertility
Interventions
Comprehensive Chromosome Screening, Morphologically Best
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Nov 3, 2026, 1:03 PM EST
Terminated Not applicable Interventional

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

NCT02363647
View directory record Official record
Conditions
Medullary Thyroid Cancer, Colon Cancer
Interventions
Tumor Genomic Analysis
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Nov 3, 2026, 1:03 PM EST